



Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022

May 17, 2022

LEXINGTON, MA, May 17, 2022 – [Fractyl Health](#), an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Disease Week meeting being held May 21-24, 2022, in San Diego, CA.

Data being presented reflect changes in gluco-regulatory hormones and insulin sensitivity in patients with type 2 diabetes after treatment with Revita® Duodenal Mucosa Resurfacing (DMR), an endoscopic procedure using hydrothermal energy to ablate and regenerate duodenal mucosa. The analysis was performed using data from the company's Revita-1 and Revita-2 clinical studies.

The presentation details are as follows:

Title: "Improvements in insulin sensitivity in patients with type 2 diabetes after Revita® DMR is associated with a decrease in glucagon, glucose, and GIP after a mixed meal tolerance test"

Presentation Number: 478

Date and Time: May 22, 2022, 2:30 p.m. PT

Presenter: Suzanne Meiring, M.D., Amsterdam University Medical Center

About Revita

Fractyl Health's lead product candidate, Revita, is based on the company's insights surrounding the potential role of the gut in metabolic diseases. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root cause of metabolic diseases. Revita has received a CE mark in Europe and in January 2022 received reimbursement authorization in Germany. In the United States, Revita is for investigational use only under US law and has received Breakthrough Device Designation from the FDA to improve glycemic control and eliminate insulin needs in T2D patients who are inadequately controlled on long-acting insulin.

About Fractyl Health

Fractyl Health is focused on pioneering a new approach to the treatment of T2D. Despite advances in treatment over the last 50 years, metabolic diseases in general, and T2D in particular, continue to be a principal and rapidly growing driver of morbidity and mortality in the 21st century. Fractyl Health's goal is to transform T2D treatment from chronic blood glucose management to disease-modifying therapies that target the organ-level root causes of the disease. Fractyl Health's lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) in order to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root cause of metabolic diseases. Fractyl Health is a private organ-editing metabolic therapeutics company based in Lexington, MA. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth.

Corporate Contact

Lisa Davidson, Chief Financial Officer

lisa@fractyl.com, 781.902.8800

Media Contact

Lisa Raffensperger, Ten Bridge Communications

lisa@tenbridgecommunications.com, 617.903.8783